Human Anti-CXCL13 (clone W253B4) scFv-Fc Chimera

CAT#: VS-0125-FY12

The scFv-Fc format integrates single-chain variable fragments (scFvs) with an Fc domain, enhancing the molecule's half-life in circulation and stability. A flexible (A4T)3 linker is employed to ensure optimal spatial orientation and functionality of the scFv domains, thereby preserving their biological activity while bolstering overall stability. Additionally, advancements in affinity for both human and cynomolgus CXCL13 have been achieved through targeted mutagenesis and selection. These improvements are essential for the therapeutic efficacy of the product, positioning it as a promising option in targeted therapies.

Gene Expression
Figure 1 IHC staining of human bone marrow Figure 2 Cerebral cortex Figure 3 Colon Figure 4 Kidney Figure 5 Testis Figure 6 Bone marrow Figure 7 RNA cell line category: Cell line enhanced (U-266/70)

Specifications

  • Host Species
  • Human
  • Type
  • Human IgG1, scFv-Fc
  • Species Reactivity
  • Human, Cynomolgus
  • Clone
  • W253B4
  • Applications
  • ELISA, Neutralization
  • Related Disease
  • Cancer

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Format
  • Liquid
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Stabilizer
  • No Stabilizers
  • Sterility
  • 0.2 μM filtered
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
  • Shipping
  • Ice packs

Applications

  • Application Notes
  • The anti-CXCL13 scFv-Fc is engineered to neutralize the chemokine CXCL13 by binding to it and preventing interaction with the CXCR5 receptor. This action plays a crucial role in modulating immune responses, as CXCL13 is known to recruit immune cells to inflamed or tumor sites. Additionally, its tetravalent bispecific format allows it to engage multiple targets, potentially enhancing therapeutic effectiveness through synergistic immune modulation. The design improvements made to the molecule focus on stability and manufacturability. These enhancements facilitate the formulation of the scFv-Fc in high concentrations. Consequently, it is suitable for subcutaneous delivery, which offers a more patient-friendly administration route compared to intravenous delivery. Overall, the anti-CXCL13 scFv-Fc holds promise in advancing immune therapies.

Target

  • Alternative Names
  • C-X-C Motif Chemokine Ligand 13; Small Inducible Cytokine B Subfamily (Cys-X-Cys Motif), Member 13 (B-Cell Chemoattractant); B Cell-Attracting Chemokine 1; B Lymphocyte Chemoattractant; Small-Inducible Cytokine B13; B-Cell Chemoattractant; CXC Chemokine BLC; SCYB13; ANGIE; BCA-1; BCA1
  • Sequence Similarities
  • Belongs to the intercrine alpha (chemokine CxC) family.
  • Cellular Localization
  • Secreted
  • Post Translation Modifications
  • Modification sites at PhosphoSitePlus
    Modification sites at neXtProt
  • Function
  • Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils.
    Does not induce calcium release in B-lymphocytes.
    Binds to BLR1/CXCR5.
REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS
Inquiry
Navs

Customer Review

Submit a review or a question

There are currently no Customer reviews or questions for VS-0125-FY12. Click the button above to contact us or submit your feedback about this product.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Article title:
DOI/PubMed URL:
Email:
Name:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

Secondary Antibody

Isotype Control

See other products for "CXCL13"

Select a product category from the dropdown menu below to view related products.

CAT Product Name Application Type
TAB-104MZ Anti-Human CXCL13 Recombinant Antibody (MAb 1476) ELISA Chimeric antibody (mouse/human)
TAB-104MZ-S(P) Anti-Human CXCL13 Recombinant Antibody scFv Fragment (MAb 1476) ELISA Chimeric antibody (mouse/human)
TAB-104MZ-F(E) Anti-Human CXCL13 Recombinant Antibody Fab Fragment (MAb 1476) ELISA Chimeric antibody (mouse/human)
CAT Product Name Application Type
BRD-0149MZ Chicken Anti-CXCL13 Polyclonal IgY WB Chicken antibody
CAT Product Name Application Type
HPAB-0060-CN-S(P) Human Anti-CXCL13 Recombinant Antibody (clone Ab 1); scFv Fragment FC, ELISA, WB, IF Human scFv
CAT Product Name Application Type
HPAB-0060-CN-F(E) Human Anti-CXCL13 Recombinant Antibody (clone Ab 1); Fab Fragment FC, ELISA, WB, IF Human Fab
CAT Product Name Application Type
VS-0125-FY62 Human Anti-CXCL13 (clone E10) scFv-Fc Chimera IA Human IgG1, scFv-Fc
Specific Inquiry
Go to compare Add to compare

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare